Search - tctmd.com

Displaying 81 - 100 of 345

Sort: Relevancy | Date

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Daily News

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Michael O'Riordan

December 14, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

Advertisement

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

The Left Main Debate: What Does it Mean for the Future of Intervention?

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content